InvestSMART

Immutep Limited (ASX: IMM) - Announcements

- Current share price for IMM : $0.023

ASX company news and announcements for Immutep Limited (IMM) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Immutep Limited (IMM) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Immutep Limited (IMM), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Immutep Limited (IMM)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$34 Trading Halt 27 Apr 2020 9:21AM $0.175 $0.023 fallen by 86.86%
$34 Enrollment completed for the INSIGHT-004 Study 22 Apr 2020 8:17AM $0.150 $0.023 fallen by 84.67%
$34 Immutep March Quarterly Activities Report & Appendix 4C 20 Apr 2020 10:19AM $0.160 $0.023 fallen by 85.63%
$34 Immutep advances its LAG-3 agonist for autoimmune diseases 16 Apr 2020 8:53AM $0.165 $0.023 fallen by 86.06%
$34 Immutep presents TACTI-002 data at AACR Virtual Meeting 14 Apr 2020 11:30AM $0.140 $0.023 fallen by 83.57%
$34 EOC Pharma confirms plans to advance Efti in China for MBC 8 Apr 2020 11:17AM $0.125 $0.023 fallen by 81.60%
$34 Immutep AIPAC Ph2b Clinical Results & Update Webcast Slides 26 Mar 2020 8:29AM $0.170 $0.023 fallen by 86.47%
$34 Immutep reports supportive efficacy data from AIPAC study 25 Mar 2020 9:24AM $0.300 $0.023 fallen by 92.33%
$34 Immutep's Partner, EOC completes recruitment of Phase 1 20 Mar 2020 8:25AM $0.290 $0.023 fallen by 92.07%
$34 Change of Director's Interest Notice - Mr Chamberlain 16 Mar 2020 4:54PM $0.280 $0.023 fallen by 91.79%
$34 Immutep receives 2nd IND approval for efti from US FDA 9 Mar 2020 8:26AM $0.355 $0.023 fallen by 93.52%
$34 Change in substantial holding 2 Mar 2020 8:17AM $0.330 $0.023 fallen by 93.03%
$34 Immutep Clinical Update & Results Global Webcast Slides 25 Feb 2020 5:41PM $0.430 $0.023 fallen by 94.65%
$34 Change in substantial holding 21 Feb 2020 8:16AM $0.400 $0.023 fallen by 94.25%
$34 Half Yearly Report and Accounts 21 Feb 2020 8:14AM $0.400 $0.023 fallen by 94.25%
$34 Immutep reports positive TACTI-002 data 19 Feb 2020 8:14AM $0.390 $0.023 fallen by 94.10%
$34 Change in substantial holding 5 Feb 2020 8:51AM $0.320 $0.023 fallen by 92.81%
$34 Immutep to present TACTI-002 data at German Cancer Congress 4 Feb 2020 8:19AM $0.325 $0.023 fallen by 92.92%
$34 Immutep Activities Report 29 Jan 2020 9:41AM $0.275 $0.023 fallen by 91.64%
$34 Appendix 4C - quarterly 29 Jan 2020 9:02AM $0.275 $0.023 fallen by 91.64%
$34 Immutep Corporate Presentation 10 Jan 2020 9:53AM $0.285 $0.023 fallen by 91.93%
$34 Immutep expands Part C of TACTI-002 due to positive data 9 Jan 2020 8:23AM $0.265 $0.023 fallen by 91.32%
$34 Change in substantial holding 6 Jan 2020 8:18AM $0.260 $0.023 fallen by 91.15%
$34 Change of Director's Interest Notice 2 Jan 2020 8:19PM $0.260 $0.023 fallen by 91.15%
$34 Appendix 3B 2 Jan 2020 4:19PM $0.260 $0.023 fallen by 91.15%

601 - 625 of 790 results

Page 25 of 32

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.